Clinical Characteristics And Curative Effect Evaluation Of 22 Cases Of Breast Cancer With Radiofrequency Ablation

Objective:Breast cancer is one of the most common malignancies in women.About 10%of every woman has a risk of developing breast cancer in a lifetime.About 20%of patients experience local recurrence or distant metastasis.Over the past few decades,adjuvant therapy has significantly improved survival in patients with primary breast cancer.But the prognosis of breast cancer patients with liver metastases is still poor.Liver resection and local ablation in colorectal cancer patients with liver metastases is already recognized as safe and effective therapy,these technologies on breast cancer patients with liver metastases is also a matter of concern to everyone.In this study,from 2007 to 2016 in the Second Affiliated Hospital of Zhejiang University Medical College received radiofrequency ablation of 22 patients with breast cancer liver metastases in patients with clinical features and progression-free survival and survival analysis,to find the breast cancer liver Metastasis of patients after radiofrequency ablation without progression of survival factors,and to estimate the prognosis of patients.Materials and Methods:We retrospectively analyzed the clinical features,median progression-free survival and prognosis of 22 patients with breast cancer who had detailed medical records and follow-up data from 2007 to 2016 at the Second Affiliated Hospital of Zhejiang University Medical College.Risk factors.The pathogenesis of breast cancer,estrogen receptor,progesterone receptor,Cerb-2,primary axillary lymph node metastasis,the incidence of breast cancer,the incidence of breast cancer,the time of menopause,the operation of breast cancer,,The recovery of liver metastases when combined with other parts of the situation,postoperative adjuvant treatment of breast cancer,confirmed liver metastases time,the first row of RFA treatment time,RFA treatment after adjuvant therapy,no progress after RFA survival time,total survival,Family history,fertility history.To analyze the effect of these clinical features on the progression-free survival of patients after radiofrequency ablation.Statistical analysis using Kaplan-Meier method,log-rank test.Results:1.All 22 patients were female,the median age of onset was 46 y/o(28-65 y/o).The median PFS was 11.8±3.6(95%CI:4.7-18.9)in all cases.2.The median survival time of RFA in all cases was 23.8 ± 5.8 months(95%CI:12.5-35.2)(from 2.7 to 93.2 months).The median survival time was 38.9±3.6 months(95%CI:36.8-46.1)after diagnosis of liver metastases(from 10.8 to 98.5 months).3.The primary tumor axillary lymph node metastasis,liver metastases for the single foci or multiple foci,breast cancer after the initial diagnosis of liver metastases time interval,the first time after the completion of liver metastases RFA treatment interval and RFA postoperative PFS Correlation,but no significant difference(P>0.05).4.We can not prove the age of breast cancer,breast cancer incidence of menopause,ER status,PR state,Her-2 state,liver metastases single or multiple circumstances,the diagnosis of liver metastases when combined with other parts of the transfer with PFS Significant relevance.Conclusion:1.The timing of axillary lymph node staging and the initial diagnosis of liver metastases after breast cancer.The time interval of RFA treatment after primary liver metastases had an effect on PFS after RFA treatment.The earlier liver metastases were found after breast cancer surgery.The later the post-treatment time,the better the prognosis;2.The progression-free survival time(11.8 months)after RFA in this study was similar to that reported in the literature(11 months).The overall survival(38.9 months)was higher than that of liver TACE(26 months),similar to liver resection(20-67 months).3.Breast cancer patients with liver metastases can benefit from RFA surgery.